BRPI0606279A2 - tratamento de doença inflamatória do intestino - Google Patents

tratamento de doença inflamatória do intestino

Info

Publication number
BRPI0606279A2
BRPI0606279A2 BRPI0606279-2A BRPI0606279A BRPI0606279A2 BR PI0606279 A2 BRPI0606279 A2 BR PI0606279A2 BR PI0606279 A BRPI0606279 A BR PI0606279A BR PI0606279 A2 BRPI0606279 A2 BR PI0606279A2
Authority
BR
Brazil
Prior art keywords
treatment
inflammatory bowel
bowel disease
disease
compound
Prior art date
Application number
BRPI0606279-2A
Other languages
English (en)
Inventor
Yariv Donde
Jeremiah H Nguyen
Daniel W Gil
John E Donello
Karen M Kedzie
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0606279A2 publication Critical patent/BRPI0606279A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/46—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid
    • C07C57/48—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings and other rings, e.g. cyclohexylphenylacetic acid having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

TRATAMENTO DE DOENçA INFLAMATóRIA DO INTESTINO. Aqui é descrito um método compreendendo administrar um composto a um mamífero que sofre de uma doença inflamatória do intestino para o tratamento da referida doença, o referido composto tendo uma estrutura de acordo com a Fórmula I.
BRPI0606279-2A 2005-03-17 2006-03-14 tratamento de doença inflamatória do intestino BRPI0606279A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/084,454 US7855226B2 (en) 2003-02-11 2005-03-17 Treatment of inflammatory bowel disease
PCT/US2006/009222 WO2006101867A2 (en) 2005-03-17 2006-03-14 Treatment of inflammatory bowel disease

Publications (1)

Publication Number Publication Date
BRPI0606279A2 true BRPI0606279A2 (pt) 2009-06-09

Family

ID=37024345

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606279-2A BRPI0606279A2 (pt) 2005-03-17 2006-03-14 tratamento de doença inflamatória do intestino

Country Status (7)

Country Link
US (4) US7855226B2 (pt)
EP (1) EP1858592A2 (pt)
JP (1) JP2008533158A (pt)
AU (1) AU2006227693A1 (pt)
BR (1) BRPI0606279A2 (pt)
CA (1) CA2601096C (pt)
WO (1) WO2006101867A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
EP2465506A1 (en) 2006-12-18 2012-06-20 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders
ES2727787T3 (es) 2009-11-15 2019-10-18 Univ Indiana Res & Tech Corp Métodos para mejorar el suministro y el injerto de células madre incluida la identificación de receptores específicos de prostaglandina E2
PH12013500205A1 (en) 2010-07-30 2017-08-23 Allergan Inc Compounds and methods for skin repair
BR112013003600A2 (pt) 2010-08-17 2016-08-16 Allergan Inc agonistas ep2 ou ep4 para o tratamento de névoa da córnea
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012024072A1 (en) 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US20120142684A1 (en) 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
WO2012112757A2 (en) 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
CA2832589A1 (en) 2011-04-07 2012-10-11 Allergan, Inc. Devices, compositions and methods utilizing ep4 and ep2 receptor agonists for preventing, reducing or treating capsular contracture
EP2814527A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123272A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123270A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814526B1 (en) 2012-02-16 2016-11-02 Allergan, Inc. Compositions and improved soft tissue replacement methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS492972A (pt) 1972-05-04 1974-01-11
US4117014A (en) 1976-01-09 1978-09-26 Abbott Laboratories Prostaglandin derivatives
JPS59101458A (ja) 1982-12-01 1984-06-12 Nippon Iyakuhin Kogyo Kk 新規なチアプロスタグランジン誘導体及びその製法
JPS632972A (ja) 1986-06-20 1988-01-07 Nippon Iyakuhin Kogyo Kk 新規プロスタグランジンｅ↓１誘導体及びその製法
US4959311A (en) 1988-03-31 1990-09-25 North Carolina State University Method of degrading keratinaceous material and bacteria useful therefore
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US4994274A (en) 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5446047A (en) 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
TWI249520B (en) * 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6531504B2 (en) 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US20030027853A1 (en) * 2001-06-14 2003-02-06 Allergan Sales, Inc. 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US20050222094A1 (en) * 2001-06-14 2005-10-06 Burk Robert M Treatment of inflammatory bowel disease
US7872045B2 (en) * 2001-06-14 2011-01-18 Allergan, Inc. Combination therapy for glaucoma treatment
ES2246419T3 (es) 2001-11-05 2006-02-16 Allergan, Inc. Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep-2.
CA2515631C (en) 2003-02-11 2013-08-20 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US7855226B2 (en) * 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6875787B2 (en) * 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
TWI386208B (zh) * 2005-04-18 2013-02-21 Allergan Inc 治療性的經取代環戊酮
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
EP2465506A1 (en) * 2006-12-18 2012-06-20 Allergan, Inc. Methods and compositions for treating gastrointestinal disorders

Also Published As

Publication number Publication date
WO2006101867A3 (en) 2007-06-07
US20110172435A1 (en) 2011-07-14
CA2601096C (en) 2012-10-23
US20150018400A1 (en) 2015-01-15
US8754122B2 (en) 2014-06-17
CA2601096A1 (en) 2006-09-28
US9156810B2 (en) 2015-10-13
EP1858592A2 (en) 2007-11-28
WO2006101867A2 (en) 2006-09-28
AU2006227693A1 (en) 2006-09-28
JP2008533158A (ja) 2008-08-21
US20050164992A1 (en) 2005-07-28
US20160096817A1 (en) 2016-04-07
US9637467B2 (en) 2017-05-02
US7855226B2 (en) 2010-12-21

Similar Documents

Publication Publication Date Title
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
AR109995A2 (es) Método para inhibir la resorción ósea
NO20083885L (no) Fremgangsmate for behandling av inflammatoriske sykdommer
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
BRPI0515546A (pt) compostos para inflamação e usos imune-relacionados
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0512916A (pt) derivado de tienopirazol tendo atividade inibidora de pde 7
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
EA200701504A1 (ru) Индолы, пригодные для лечения воспалений
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DE602005016929D1 (de) Liganden für den cannabinoidrezeptoren
EP2200597A4 (en) METHOD FOR RESTRICTING OXIDATIVE STRESS AND FOR IMPROVING WORKING CONCEPTS BY ADMINISTERING PTEROSTILES
EA200970512A1 (ru) Лечение по поводу множественной миеломы
EA201100910A1 (ru) Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
EA200801596A1 (ru) Новые 11-бета-гидроксиандроста-4-ен-3-оны
CR6824A (es) Derivados de arilmetilamina para uso como inhibidores de triptasa
EA201401231A1 (ru) Фармацевтические комбинации, предназначенные для лечения метаболических нарушений
EA201001496A1 (ru) Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
EA200870433A1 (ru) Азагетероциклильные производные андростанов и андростенов в качестве лекарственных средств от сердечно-сосудистых расстройств
UY31325A1 (es) Composiciones y métodos para tratar enfermedades y trastornos inmunologicos e inflamatorios

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 11A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/5575 (2006.01), A61P 29/00 (2006.01)